Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

Emergent BioSolutions (EBS) Misses Q4 EPS by 35c; Offers FY23 Revenue Guidance

February 27, 2023 4:44 PM EST

Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.31), $0.35 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $331 million versus the consensus estimate of $297.18 million.

GUIDANCE:

Emergent BioSolutions sees FY2023 revenue of $1.15 billion, versus the consensus of $1.18... More